Synaptiflora develops an AI foundation model that integrates microbiome, genomic, and clinical data to provide pharmaceutical companies with precise insights for drug development. This approach addresses the inefficiencies in drug discovery processes, aiming to reduce the high failure rates and costs associated with bringing new therapies to market.
Funding
Funding not disclosed
Founders
Product
Problem
The current drug development process is inefficient, with high failure rates and substantial costs, partly due to the lack of integrated microbiome data with genomic and clinical insights. Pharmaceutical companies need better solutions to streamline drug development and improve the success rate of bringing new therapies to market.
Solution
Synaptiflora offers an AI foundation model, SynaptiCore, that integrates microbiome composition, metabolomics, and host interactions to provide pharmaceutical companies with precise insights for drug development. This platform deciphers the complex relationships between the microbiome, host genetics, and metabolic pathways, delivering actionable insights for patient stratification, efficacy prediction, and trial optimization. Synaptiflora's scalable SaaS platform transforms SynaptiCore into specialized, disease-specific tools tailored for pharmaceutical R&D and clinical trials, accelerating the journey to effective therapies.
Target Audience
Synaptiflora primarily targets pharmaceutical companies involved in drug development, research and development, and clinical trials.
Features
- AI foundation model built on a curated dataset integrating microbiome composition, metabolomics, and host interactions
- Scalable SaaS platform transforming SynaptiCore into disease-specific tools
- Translational Modeling Package for pharmaceutical R&D
- Trial Optimization Package for clinical trials
- Actionable insights for patient stratification and efficacy prediction
- Tools for optimizing clinical trials